{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:53:06Z","timestamp":1792284786883,"version":"4.4.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018987","name":"Romanian Government Ministry of Research Innovation and Digitization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018987","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006529","name":"Race and Difference Initiative, Emory University","doi-asserted-by":"publisher","award":["29 PFE\/30.12.2021"],"award-info":[{"award-number":["29 PFE\/30.12.2021"]}],"id":[{"id":"10.13039\/100006529","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.biopha.2022.113614","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T06:59:36Z","timestamp":1662015576000},"page":"113614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["In-depth bibliometric analysis and current scientific mapping research in the context of rheumatoid arthritis pharmacotherapy"],"prefix":"10.1016","volume":"154","author":[{"given":"Andrei-Flavius","family":"Radu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona Gabriela","family":"Bungau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Andrei","family":"Negru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai Florin","family":"Marcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia Liana","family":"Andronie-Cioara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.113614_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102735","article-title":"Beyond the joints, the extra-articular manifestations in rheumatoid arthritis","volume":"20","author":"Conforti","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.biopha.2022.113614_bib2","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/cells9040880","article-title":"Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis","volume":"9","author":"Lin","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2022.113614_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41413-018-0016-9","article-title":"Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies","volume":"6","author":"Guo","year":"2018","journal-title":"Bone Res"},{"key":"10.1016\/j.biopha.2022.113614_bib4","article-title":"Promising therapeutic targets for treatment of rheumatoid arthritis","volume":"12","author":"Huang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2022.113614_bib5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/art.41417","article-title":"Rheumatoid Arthritis: Pathogenesis, Prediction and Prevention \u2013 An Emerging Paradigm Shift","volume":"73","author":"Deane","year":"2021","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.biopha.2022.113614_bib6","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.21739","article-title":"The HLA\u2013DRB1 shared epitope alleles are primarily a risk factor for anti\u2013cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis","volume":"54","author":"van der Helm-van Mil","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2022.113614_bib7","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.3390\/cells10112857","article-title":"Management of rheumatoid arthritis: an overview","volume":"10","author":"Radu","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2022.113614_bib8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18053\/jctres.02.201603.005","article-title":"The role of TNF-\u03b1 in rheumatoid arthritis: a focus on regulatory T cells","volume":"2","author":"Farrugia","year":"2016","journal-title":"J. Clin. Transl. Res."},{"key":"10.1016\/j.biopha.2022.113614_bib9","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s10787-021-00884-x","article-title":"Exploring the therapeutic promise of targeting Rho kinase in rheumatoid arthritis","volume":"29","author":"Singh","year":"2021","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.biopha.2022.113614_bib10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10456-015-9477-2","article-title":"The pathogenic role of angiogenesis in rheumatoid arthritis","volume":"18","author":"Elshabrawy","year":"2015","journal-title":"Angiogenesis"},{"key":"10.1016\/j.biopha.2022.113614_bib11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/ar2107","article-title":"Cells of the synovium in rheumatoid arthritis. T lymphocytes","volume":"9","author":"Lundy","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.biopha.2022.113614_bib12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/1759720X12438080","article-title":"The role of RANK ligand\/osteoprotegerin in rheumatoid arthritis","volume":"4","author":"Geusens","year":"2012","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.biopha.2022.113614_bib13","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2022.113614_bib14","first-page":"1316","article-title":"The role of imaging in rheumatoid arthritis","volume":"22","author":"Kgoebane","year":"2018","journal-title":"SA J. Radiol."},{"key":"10.1016\/j.biopha.2022.113614_bib15","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3390\/jcm8070938","article-title":"Current therapeutic options in the treatment of rheumatoid arthritis","volume":"8","author":"K\u00f6hler","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biopha.2022.113614_bib16","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.12688\/f1000research.18688.1","article-title":"Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies","volume":"8","author":"Senolt","year":"2019","journal-title":"F1000Research"},{"key":"10.1016\/j.biopha.2022.113614_bib17","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.biopha.2022.113614_bib18","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2022.113614_bib19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.reuma.2017.07.020","article-title":"Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis","volume":"15","author":"Alfaro-Lara","year":"2019","journal-title":"Reumatol. Cl\u00ednic."},{"key":"10.1016\/j.biopha.2022.113614_bib20","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.mayocp.2020.01.039","article-title":"Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis","volume":"95","author":"Wang","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.biopha.2022.113614_bib21","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3390\/biom10071002","article-title":"JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future","volume":"10","author":"Angelini","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2022.113614_bib22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/cells10020323","article-title":"Biologic drugs for rheumatoid arthritis in the context of biosimilars, genetics, epigenetics and COVID-19 treatment","volume":"10","author":"Bonek","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2022.113614_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1142\/S0219622020500406","article-title":"Analysis of collaboration evolution in AHP Research: 1982-2018","volume":"20","author":"Yu","year":"2021","journal-title":"Int. J. Inf. Technol. Decis. Mak."},{"key":"10.1016\/j.biopha.2022.113614_bib24","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/int.21894","article-title":"Exploring the ordered weighted averaging operator knowledge domain: a bibliometric","volume":"32","author":"He","year":"2017","journal-title":"Anal., Int. J. Intell. Syst."},{"key":"10.1016\/j.biopha.2022.113614_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.eswa.2020.114238","article-title":"Tracing knowledge diffusion of TOPSIS: a historical perspective from citation network","volume":"168","author":"Yu","year":"2021","journal-title":"Expert Syst. Appl."},{"key":"10.1016\/j.biopha.2022.113614_bib26","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis","volume":"343","author":"Bombardier","year":"2000","journal-title":"VIGOR Study Group, N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113614_bib27","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113614_bib28","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/34184","article-title":"PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines","volume":"391","author":"Jiang","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.113614_bib29","first-page":"1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial","volume":"284","author":"Silverstein","year":"2000","journal-title":"Celecoxib Long. Term. Arthritis Saf. Study, JAMA"},{"key":"10.1016\/j.biopha.2022.113614_bib30","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2022.113614_bib31","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113614_bib32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113614_bib33","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","article-title":"Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs","volume":"340","author":"Wolfe","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113614_bib34","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113614_bib35","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113614_bib36","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113614_bib37","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with Infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113614_bib38","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0753-3322(02)00253-6","article-title":"The importance of the ratio of omega-6\/omega-3 essential fatty acids","volume":"56","author":"Simopoulos","year":"2002","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2022.113614_bib39","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113614_bib40","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113614_bib41","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2022.113614_bib42","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2022.113614_bib43","doi-asserted-by":"crossref","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.biopha.2022.113614_bib44","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2022.113614_bib45","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2022.113614_bib46","first-page":"1","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.biopha.2022.113614_bib47","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.biopha.2022.113614_bib48","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1080\/14712598.2017.1346078","article-title":"Safety profile of biological therapies for treating rheumatoid arthritis","volume":"17","author":"Ca\u00f1ete","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.biopha.2022.113614_bib49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bbapap.2003.09.015","article-title":"A pattern of protein expression in peripheral blood mononuclear cells distinguishes rheumatoid arthritis patients from healthy individuals","volume":"1696","author":"Dotzlaw","year":"2004","journal-title":"Biochim. Biophys. Acta Proteins Proteom."},{"key":"10.1016\/j.biopha.2022.113614_bib50","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s10067-020-05016-4","article-title":"The road to rheumatoid arthritis prevention: challenges and opportunities","volume":"39","author":"Chaichian","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.biopha.2022.113614_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1759720X221076211","article-title":"A broad look into the future of rheumatoid arthritis","volume":"14","author":"Mucke","year":"2022","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.biopha.2022.113614_bib52","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/08916934.2013.873413","article-title":"Therapeutic targets for rheumatoid arthritis: Progress and promises","volume":"47","author":"Alghasham","year":"2014","journal-title":"Autoimmunity"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222010034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222010034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:37:42Z","timestamp":1791661062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222010034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":52,"alternative-id":["S0753332222010034"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113614","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In-depth bibliometric analysis and current scientific mapping research in the context of rheumatoid arthritis pharmacotherapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113614","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113614"}}